Condition

MdDS Treatment: Mal de Débarquement Syndrome

Clinically reviewed by Dr. Dalia El-Hag, PT, DPT, NCSUpdated October 7, 2026
Book a 15 min call

Free, 15 minutes. It is a clinical fit conversation, not a sales screen.

If you walked off a cruise, a flight, or a long drive weeks ago and you're still rocking — and it eases when you drive, then returns the moment you stop — that has a name: mal de débarquement syndrome. MdDS is real, formally defined, and studied; most providers have simply never seen it. MindForge provides criteria-literate evaluation and readaptation-based retraining in Dallas. Free 15-minute call · (214) 730-6463.

MindForge doesn't bill insurance — by design. Direct-pay is what makes an individualized, intensive program possible rather than care shaped by billing codes. HSA/FSA and financing options exist, and a written Good Faith Estimate precedes any commitment.

What MdDS is

Aboard a ship or plane, your brain builds an internal model of the motion — and adapts brilliantly. MdDS is that adaptation failing to release: persistent rocking, swaying, or bobbing perception lasting beyond a month after passive-motion exposure (a spontaneous-onset variant exists too), with the pathognomonic signature that re-exposure to passive motion — riding in a car — temporarily relieves it [1]. It skews strongly female, typically onsets in the 40s–50s [1], and is routinely misdiagnosed as vestibular migraine, Ménière's, or anxiety — when it's recognized at all.

That relieved-by-driving paradox deserves a sentence of its own, because it's the detail that makes many patients doubt themselves: a symptom that improves in motion sounds backwards until you understand the mechanism — and then it's practically diagnostic.

The specialist runaround

The typical MdDS path: ENT (ears normal), neurology (scans normal), cardiology (heart fine), a motion-sickness pill that does nothing — because vestibular test batteries in MdDS are characteristically normal, which is itself diagnostic information when the history fits [1]. Being cleared by everyone while still rocking is not evidence you're imagining it; it's the textbook presentation of a condition most clinics have never treated. We have — and the highly organized MdDS patient community is a large part of why patients find their way to criteria-literate care at all.

How we evaluate MdDS: the Discovery Day

The MindForge Discovery Day — comprehensive neurological evaluation + report of findings + care plan. MdDS evaluation: the structured onset-and-pattern discriminator (passive-motion onset, rocking quality, motion-relief — the history IS the backbone), symptom instruments, and the full objective battery — where documenting normal peripheral function alongside the classic history is precisely the diagnostic value [1]. Overlap screening for PPPD and vestibular migraine, which coexist and mimic. Same-day findings, written GFE, routing by name.

Treatment: the MdDS Intensive

Failed generic advice: "it'll fade on its own" (after months, it often hasn't), suppressant medications (characteristically ineffective for MdDS), or serial clearance with no plan. Counter-thesis: MdDS behaves like a maladapted internal motion model — and the published treatment lane is readaptation: retraining the vestibulo-ocular system to release the stored motion pattern. The strongest published signal comes from a readaptation-protocol research cohort (n=141, 2017 follow-up): 78% of classic-onset patients significantly improved (≥50% symptom reduction) after the treatment week, with roughly half maintaining significant improvement at one year, and earlier treatment and younger age predicting better outcomes [2]. Those are published research-cohort outcomes, not MindForge outcomes — we cite them because they define what's possible in the lane we work in: vestibular readaptation retraining (our specific protocol implementation per clinical sign-off), supported by gaze/oculomotor work, balance re-education, graded conditioning, FM support for sleep and stress physiology, and pacing.

The caveats, printed: response rates decline with chronicity; recurrence after future passive-motion exposure (travel) is documented in the same research [2]; no cure claims. Program pricing is shared on your free 15-minute call (exact quote + GFE at the wrap).

What treatment looks like: Discovery Day → a concentrated retraining week(s) → re-test and a travel-planning conversation (what to expect). MdDS is a classic traveler condition — patients fly in for exactly this.

Costs: DD = one fixed fee, shared on your call · program pricing on the same call + GFE · ways to pay. Schedule: 15-min call → Discovery Day scheduled live on your call → program typically within days.

Frequently asked questions

Is MdDS real?

Yes — formally defined (Bárány criteria, 2020 [1]), studied, and treated in a published research lane [2]. Most providers have simply never met it.

Why does driving help?

Passive motion temporarily re-engages the stored motion model — the paradox is characteristic, not contradictory.

My vestibular tests were normal — so what's wrong?

Normal peripheral tests WITH the classic history is the expected MdDS picture [1] — the pattern is the diagnosis.

Can it be cured?

Published cohorts show meaningful, durable improvement for many — alongside declining response with chronicity and documented recurrence risk [2]. We promise measurement, not cures.

Will it come back if I travel?

Recurrence after re-exposure is documented [2]; we plan travel strategy with you at re-test.

MdDS vs PPPD?

Constant rocking relieved by motion versus dizziness worsened by motion and visual complexity — see the PPPD page; they can coexist.

Do you take insurance?

We're direct-pay, with superbills provided — see ways to pay.

Sources: [1] MdDS diagnostic criteria (Cha et al., Bárány Society/J Vestib Res, 2020); epidemiology and clinical profile (Cha, 2018). [2] VOR-readaptation research lane: Dai et al., Frontiers in Neurology 2014 (initial cohort) and 2017 one-year follow-up (n=141): 78% classic-onset significant improvement post-treatment-week; ~52%/48% (classic/spontaneous) retained at 1 year; complete remission 27%/19%; earlier treatment and younger age favorable.

Turning something off stops it running on this site from now on. Cookies those services have already set sit on their own domains, so we cannot delete them from here — your browser settings can.

Read the cookie policy